MARKET

ARDX

ARDX

Ardelyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.42
-0.19
-2.80%
After Hours: 6.42 0 0.00% 16:00 07/10 EDT
OPEN
6.62
PREV CLOSE
6.61
HIGH
6.68
LOW
6.42
VOLUME
423.15K
TURNOVER
--
52 WEEK HIGH
8.82
52 WEEK LOW
2.100
MARKET CAP
571.74M
P/E (TTM)
-4.8784
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARDX stock price target is 13.00 with a high estimate of 15.00 and a low estimate of 11.00.

EPS

ARDX News

More
Mixed shelf roundup - healthcare
The following medical companies have filed for mixed shelf offerings: Ardelyx (ARDX -4.5%): $250M. Vaxart (VXRT +1.7%): $100M. Alpine Immune Sciences (ALPN
seekingalpha · 1d ago
Ardelyx (ARDX) Upgraded to Buy: What Does It Mean for the Stock?
Ardelyx (ARDX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 2d ago
Ardelyx files U.S. application for tenapanor
Seeking Alpha - Article · 06/30 14:08
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
PR Newswire · 06/30 13:00
Ardelyx Submits New Drug Application To FDA For Tenapanor For Control Of Serum Phosphorus In Adult Patients With CKD On Dialysis
FREMONT, Calif., June 30, 2020 /PRNewswire/ --Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and
Benzinga · 06/30 12:04
Insider Weekends: Harold Hamm Buys More Of Continental Resources
Seeking Alpha - Article · 06/29 06:03
Independent Chairman David Mott Just Bought 133% More Shares In Ardelyx, Inc. (NASDAQ:ARDX)
Simply Wall St. · 06/28 13:30
Hedge Funds Are Dumping Ardelyx Inc (ARDX)
In this article we will take a look at whether hedge funds think Ardelyx Inc (NASDAQ:ARDX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Iv
Insider Monkey · 06/19 16:45

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ARDX

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
More

Webull offers kinds of Ardelyx Inc stock information, including NASDAQ:ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.